17 OH Progesterone (AKU) Test in Karachi at Dr. Essa Lab

17 OH Progesterone (AKU) at Dr. Essa Lab

The 17 OH Progesterone (AKU) test is a highly specialized endocrine investigation designed to measure the concentration of 17-hydroxyprogesterone (17-OHP) in the blood. This steroid hormone is an essential intermediary in the complex biosynthetic pathway that converts cholesterol into cortisol, aldosterone, and various androgens. Produced primarily by the adrenal cortex and, to a lesser extent, by the gonads and placenta, 17-OHP serves as a critical biomarker for evaluating adrenal gland function and identifying enzymatic blocks in steroidogenesis. The “AKU” designation indicates that the assay is processed utilizing advanced reference laboratory standards, ensuring the highest level of analytical precision and clinical reliability for patients and physicians across Pakistan.

Understanding the biochemical pathway of 17-OHP is essential to appreciating its clinical value. Under normal physiological conditions, the enzyme 21-hydroxylase converts 17-hydroxyprogesterone into 11-deoxycortisol, which is subsequently converted into cortisol. If there is a deficiency or complete absence of the 21-hydroxylase enzyme, this metabolic pathway is blocked. As a result, the adrenal glands cannot produce sufficient cortisol, and the precursor hormone, 17-OHP, accumulates in the bloodstream. This accumulation is the primary diagnostic hallmark of Congenital Adrenal Hyperplasia (CAH), a group of inherited autosomal recessive disorders. By measuring 17-OHP levels, endocrinologists, pediatricians, and gynecologists can accurately diagnose CAH, differentiate it from other endocrine disorders, and monitor the efficacy of hormone replacement therapies.

At Dr. Essa Lab, this test is performed using state-of-the-art immunoassay technology, such as Chemiluminescence Immunoassay (CLIA) or Liquid Chromatography-Mass Spectrometry (LC-MS/MS) reference protocols. These advanced methodologies provide exceptional sensitivity and specificity, allowing for the detection of even minute fluctuations in hormone levels. The anatomical structures indirectly evaluated through this test include the adrenal cortex—specifically the zona fasciculata and zona reticularis—as well as the hypothalamic-pituitary-adrenal (HPA) axis, which regulates hormone production through a negative feedback loop involving adrenocorticotropic hormone (ACTH). The diagnostic value of this test is immense, offering a non-invasive, highly accurate means of preventing life-threatening adrenal crises in newborns and managing complex reproductive and metabolic concerns in adults.

Clinical Procedure: What to Expect

Patient Preparation

To ensure the utmost accuracy of your 17 OH Progesterone (AKU) test results, specific preparation protocols must be followed. Because hormone levels fluctuate naturally throughout the day and during the menstrual cycle, adherence to these guidelines is critical:

• Diurnal Variation and Timing: Cortisol and its precursors follow a strict diurnal rhythm, peaking in the early morning hours. Therefore, it is highly recommended that the blood sample be collected early in the morning, typically between 7:00 AM and 9:00 AM.
• Menstrual Cycle Timing: For menstruating adolescent girls and adult women, the timing of the test is crucial. The sample should ideally be collected during the early follicular phase of the menstrual cycle (usually days 1 through 5, with day 1 being the first day of menstrual bleeding). This timing helps establish an accurate baseline, as 17-OHP levels naturally rise during the luteal phase.
• Fasting Guidelines: While strict fasting is not always mandatory for this specific hormone test, a light fasting period of 8 to 12 hours is often recommended to minimize potential interference from dietary lipids in the blood sample. Patients may drink plain water during this period.
• Medication Disclosure: It is imperative to inform your healthcare provider and the laboratory staff at Dr. Essa Lab about all medications, supplements, and hormonal therapies you are currently taking. Glucocorticoids (such as hydrocortisone, prednisone, or dexamethasone), oral contraceptives, and progesterone supplements can significantly alter test results and must be carefully documented.
• Stress Management: Physical and emotional stress can stimulate the HPA axis, leading to transient elevations in ACTH and adrenal hormones. Patients are advised to rest quietly for 15 to 20 minutes before the blood draw to ensure physiological stability.

During the Procedure

The 17 OH Progesterone (AKU) test is a standard venipuncture procedure performed by highly trained phlebotomists at Dr. Essa Lab. The process is designed to be swift, safe, and minimally invasive:

• Patient Positioning: You will be asked to sit comfortably in a specialized phlebotomy chair or lie down on an examination table. The phlebotomist will ask you to extend your arm, exposing the antecubital fossa (the inner elbow area).
• Site Selection and Sanitization: The phlebotomist will inspect your veins and select a suitable vein for access. The skin over the selected vein is thoroughly cleansed with an antiseptic solution (such as 70% isopropyl alcohol) and allowed to air dry to prevent specimen contamination and local infection.
• Tourniquet Application: A soft elastic tourniquet is tied around your upper arm to restrict venous blood flow temporarily, causing the veins to swell and become more visible and accessible.
• Venipuncture and Sample Collection: Using a sterile, single-use needle attached to a vacuum collection tube (typically a gold-top serum separator tube or a red-top clot activator tube), the phlebotomist gently inserts the needle into the vein. You may feel a brief, minor pinch or stinging sensation as the needle enters the skin.
• Tube Filling and Tourniquet Release: As blood flows into the collection tube, the tourniquet is released to restore normal circulation. Once the required volume of blood is collected, the needle is carefully withdrawn.
• Post-Draw Care: Immediate pressure is applied to the puncture site with a sterile cotton ball or gauze pad to promote hemostasis and prevent hematoma formation. A small adhesive bandage is then applied over the site.
• Safety and Comfort: The entire procedure takes less than five minutes. The phlebotomist will verify your identification details on the tube label immediately after collection to ensure absolute specimen traceability.

When is a 17 OH Progesterone (AKU) Performed?

Screening for Congenital Adrenal Hyperplasia (CAH) in Newborns

The primary and most critical clinical indication for the 17 OH Progesterone (AKU) test is the screening and diagnosis of Congenital Adrenal Hyperplasia (CAH) in neonates. CAH is a genetic disorder characterized by a deficiency in enzymes required for cortisol synthesis, most commonly 21-hydroxylase. In its classic, salt-wasting form, newborn infants can experience a life-threatening adrenal crisis within the first few weeks of life, presenting with severe dehydration, hyponatremia, hyperkalemia, vomiting, and cardiovascular collapse. Physicians request this test immediately if a newborn exhibits ambiguous genitalia, failure to thrive, or signs of adrenal insufficiency. Early detection through this assay allows for immediate glucocorticoid and mineralocorticoid replacement therapy, saving lives and preventing severe developmental complications.

Investigating Hirsutism and Virilization in Females

In adolescent girls and adult women, physicians frequently order the 17 OH Progesterone (AKU) test to investigate symptoms of androgen excess, such as hirsutism (excessive male-pattern hair growth on the face, chest, or back), severe treatment-resistant acne, and virilization (deepening of the voice, clitoromegaly, or male-pattern baldness). These symptoms can be caused by non-classic (late-onset) congenital adrenal hyperplasia, a milder form of the genetic enzyme deficiency that manifests later in life. By measuring baseline 17-OHP levels, clinicians can differentiate non-classic CAH from other common endocrine disorders, such as Polycystic Ovary Syndrome (PCOS) or androgen-secreting ovarian and adrenal tumors, ensuring the patient receives the correct targeted therapy.

Evaluating Unexplained Infertility and Menstrual Irregularities

Chronic menstrual irregularities, including oligomenorrhea (infrequent periods) and amenorrhea (absence of periods), are common clinical challenges that warrant a comprehensive endocrine workup. Elevated levels of 17-hydroxyprogesterone, even in mild cases of late-onset CAH, can disrupt the delicate hypothalamic-pituitary-ovarian axis, impairing normal follicular development and preventing ovulation. This chronic anovulation frequently leads to unexplained infertility. Gynecologists and reproductive endocrinologists utilize the 17 OH Progesterone (AKU) test to identify underlying adrenal contributions to reproductive dysfunction, allowing for specialized treatment strategies that restore ovulatory cycles and improve fertility outcomes.

Monitoring Adrenal Steroid Replacement Therapy

For patients who have already been diagnosed with Congenital Adrenal Hyperplasia, the 17 OH Progesterone (AKU) test serves as an indispensable tool for therapeutic monitoring. Patients with CAH require lifelong glucocorticoid replacement therapy (such as hydrocortisone, prednisone, or dexamethasone) to suppress the overproduction of ACTH by the pituitary gland, which in turn reduces the drive on the adrenal glands to produce excess androgens. Endocrinologists regularly monitor 17-OHP levels to assess whether the medication dosage is adequate to suppress adrenal androgen synthesis without causing exogenous Cushing’s syndrome (over-treatment). Maintaining 17-OHP within a specific target range is crucial for optimizing growth in children and maintaining metabolic and reproductive health in adults.

Diagnostic Workup for Suspected Adrenal Tumors

Although less common than enzymatic deficiencies, functional adrenal neoplasms—such as adrenocortical adenomas or carcinomas—can hypersecrete various steroid hormones and their precursors, including 17-hydroxyprogesterone. When a patient presents with an adrenal incidentaloma (an adrenal mass discovered incidentally during imaging studies) or symptoms of Cushing’s syndrome, physicians perform a comprehensive hormonal evaluation. Measuring 17-OHP levels, alongside cortisol, ACTH, and DHEA-S, helps characterize the secretory profile of the adrenal mass, assisting oncologists and endocrine surgeons in determining whether the tumor is functional and formulating an appropriate surgical or medical management plan.

What Does a 17 OH Progesterone (AKU) Detect?

The 17 OH Progesterone (AKU) test is highly sensitive to alterations in the steroidogenic pathways of the adrenal glands. Depending on the clinical context, age, and gender of the patient, this test can detect, rule out, or monitor several physiological and pathological states:

• Classic 21-Hydroxylase Deficiency (Salt-Wasting Form): Detected by extremely high concentrations of 17-OHP in newborns, indicating a severe lack of cortisol and aldosterone production.
• Classic 21-Hydroxylase Deficiency (Simple Virilizing Form): Identified in infants who present with ambiguous genitalia or early virilization but do not exhibit severe salt-wasting crises.
• Non-Classic (Late-Onset) Congenital Adrenal Hyperplasia: Characterized by moderately elevated baseline 17-OHP levels in older children, adolescents, or adults presenting with premature pubarche or androgen excess.
• Heterozygous Carriers of 21-Hydroxylase Deficiency: Detected through mild elevations in 17-OHP, particularly after an ACTH stimulation test, indicating a carrier state for the genetic mutation.
• Adrenocortical Carcinoma: Highly elevated, autonomous secretion of 17-OHP and other adrenal steroids by a malignant adrenal tumor.
• Functional Adrenal Adenomas: Benign adrenal tumors that secrete excess steroid precursors, disrupting normal endocrine balance.
• Polycystic Ovary Syndrome (PCOS) Differentiation: Helps rule out adrenal enzyme defects in patients presenting with classic PCOS symptoms, as 17-OHP levels are typically normal or only mildly elevated in PCOS.
• Ovarian Hyperthecosis: A severe form of luteinized follicular hyperplasia that can cause mild elevations in steroid precursors.
• Adrenal Incidentaloma Secretory Activity: Evaluates whether an incidentally discovered adrenal mass is biochemically active.
• Adequacy of Glucocorticoid Replacement Therapy: Detects whether a patient with CAH is receiving an optimal dose of glucocorticoids (indicated by controlled, stable 17-OHP levels).
• Under-Treatment in CAH Patients: Indicated by persistently high levels of 17-OHP, suggesting that the current glucocorticoid dose is insufficient to suppress ACTH and adrenal androgen production.
• Over-Treatment in CAH Patients: Indicated by extremely low or completely suppressed 17-OHP levels, which may put the patient at risk for glucocorticoid toxicity and growth suppression.
• Preterm Infant Physiological Elevations: Detects transiently elevated 17-OHP levels in premature infants, which must be carefully differentiated from true CAH using serial testing.
• Neonatal Stress-Induced Elevations: Identifies mild, temporary elevations in sick or stressed newborns that do not have CAH.
• Normal Luteal Phase Elevations: Detects physiological increases in 17-OHP produced by the corpus luteum during the second half of the menstrual cycle.
• Normal Gestational Elevations: Identifies physiological increases in maternal 17-OHP levels during pregnancy, produced by the placenta.
• 3-Beta-Hydroxysteroid Dehydrogenase Deficiency: A rare form of CAH that can cause secondary alterations in 17-OHP and other upstream steroid precursors.
• 11-Beta-Hydroxylase Deficiency: Another variant of CAH where 17-OHP may be moderately elevated, though 11-deoxycortisol is the primary marker.
• Hypothalamic-Pituitary-Adrenal (HPA) Axis Suppression: Detected by abnormally low levels of 17-OHP in patients undergoing chronic, high-dose exogenous corticosteroid therapy.
• Idiopathic Hirsutism: Confirmed when a patient has clinical hirsutism but completely normal 17-OHP, androgen, and ovarian profiles.
• Virilizing Ovarian Tumors: Rare ovarian neoplasms that secrete excess androgens and occasionally mild amounts of progesterone precursors.
• Adrenal Insufficiency (Addison’s Disease): Characterized by low baseline levels of 17-OHP and cortisol, with a failure to rise following ACTH stimulation.
• Enzymatic Blocks in Steroidogenesis: Maps out the specific location of enzymatic deficiencies when interpreted alongside a complete adrenal steroid panel.

Turnaround Time and Report Access at Dr. Essa Lab

At Dr. Essa Lab, we understand that waiting for diagnostic test results can be a source of anxiety for patients and their families, particularly when managing newborn health or complex endocrine conditions. Because the 17 OH Progesterone (AKU) test is a highly specialized reference assay requiring meticulous analytical processing, the standard turnaround time is typically 3 to 5 working days. This timeframe ensures that the sample undergoes rigorous quality control, calibration, and verification by our consultant pathologists and clinical biochemists.

Dr. Essa Lab provides multiple convenient methods for accessing your diagnostic reports. Once your report is finalized and signed off by our medical experts, you will receive an automated SMS notification on your registered mobile number containing a secure link to download your electronic report. Patients can also access their results directly through the official Dr. Essa Lab website by entering their lab ID and password. For those who prefer physical copies, reports can be collected from any of our conveniently located collection centers across Karachi and other major cities. Our digital reporting system is designed to facilitate seamless sharing with your treating physician, ensuring prompt clinical decision-making.

17 OH Progesterone (AKU) Findings Overview

The interpretation of 17-hydroxyprogesterone levels is highly complex, as reference ranges vary significantly based on the patient’s age, biological sex, gestational age at birth, and menstrual cycle phase. The table below provides a general clinical overview of how findings are evaluated:

Structure / Parameter Evaluated	Normal Findings	Possible Abnormal Findings
Newborns (Full-term, >3 days old)	< 2.0 ng/mL (Reference ranges may vary by birth weight)	> 10.0 ng/mL (Highly suggestive of Classic CAH; urgent pediatric endocrine evaluation required)
Preterm Infants	Typically higher than full-term infants; interpreted using specific gestational age charts	Markedly elevated levels exceeding preterm reference limits (Indicates CAH or severe neonatal stress)
Adult Males	0.3 – 2.0 ng/mL	Elevated in congenital adrenal hyperplasia, adrenal tumors, or bilateral adrenal hyperplasia
Adult Females (Follicular Phase)	0.1 – 0.8 ng/mL	Elevated in non-classic CAH, adrenal tumors, or severe ovarian hyperthecosis
Adult Females (Luteal Phase)	0.6 – 2.3 ng/mL	Elevated beyond physiological luteal limits in late-onset CAH or functional adrenal masses
Adult Females (Postmenopausal)	< 0.5 ng/mL	Elevated in functional postmenopausal adrenal tumors or late-diagnosed non-classic CAH
CAH Monitoring (Therapeutic Target)	1.0 – 10.0 ng/mL (Target range to avoid over-suppression and growth failure in pediatric patients)	< 1.0 ng/mL (Over-treatment/corticosteroid excess); > 10.0 ng/mL (Under-treatment/poor adrenal control)
Adrenal Mass Evaluation	Normal baseline levels consistent with age and sex	Markedly elevated levels (Suggests a functional, hormone-secreting adrenal adenoma or carcinoma)

Note: Diagnostic findings should always be interpreted by a qualified healthcare professional together with the patient’s symptoms, medical history, physical examination, laboratory investigations, previous imaging studies, and other relevant clinical information. Additional investigations or specialist consultation may be recommended depending on the findings.

Why Choose Dr. Essa Lab for 17 OH Progesterone (AKU)?

• Experienced Healthcare Professionals: Our laboratory is staffed by highly qualified consultant pathologists, clinical biochemists, and medical technologists specializing in complex endocrine assays.
• Patient-Focused Care: We prioritize patient comfort and safety, offering specialized, gentle phlebotomy services for infants, children, and adult patients.
• Quality Diagnostic Services: Dr. Essa Lab utilizes state-of-the-art diagnostic platforms and reference methodologies to ensure the highest analytical accuracy.
• Professional Reporting: Our reports feature clear, age- and gender-specific reference ranges to assist clinicians in making accurate diagnoses.
• Modern Diagnostic Approach: We integrate advanced reference laboratory protocols (AKU standards) to deliver reliable results for high-complexity tests.
• Comfortable Environment: All our diagnostic centers are designed to provide a clean, hygienic, and welcoming environment for patients and their families.
• Convenient Location: With an extensive network of collection centers across Karachi and other cities, accessing our services is highly convenient.
• Commitment to Accurate Diagnosis: We adhere to strict internal and external quality control programs, ensuring every test result meets international standards of excellence.